Skip to main content

Table 1 Growth factor and cytokine profiling in systemic sclerosis and control blister fluid samples

From: Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis

Biologic function   Healthy control samples SSc samples P value
Innate immunity IFNα2 5.34 (4.4 to 7.61) 6.35 (4.81 to 7.52) 0.35
  IL-1α 74.77 (22.48 to 132.28) 40.42 (15.27 to 113.19) 0.44
  IL-1B 0.37 (0.37 to 1.62) 0.62 (0.37 to 1.62) 0.57
  IL-1RA 802.5 (469.25 to 1,796.5) 695 (499.5 to 1,075.5) 0.72
  IL-6 5.51 (2.44 to 26.83) 38.78 (19.23 to 88.81) 0.01
  IL-12p40 5.16 (4.39 to 6.11) 4.58 (4.39 to 7.6) 0.86
  IL-12p70 2.03 (1.74 to 2.21) 1.99 (1.72 to 2.34) 0.87
  IL-15 4.38 (3.2 to 4.95) 6.27 (4.21 to 9.34) 0.03
  IP-10 988.5 (510.5 to 1,172.25) 1054 (547.25 to 1,929) 0.44
  TNFα 25.95 (12.15 to 65.36) 22.19 (14.46 to 44.1) 0.92
Adaptive immunity IFNγ 1.23 (1.12 to 2.76) 1.58 (1.33 to 2.76) 0.19
  IL-2 1.26 (0.73 to 1.26) 1.26 (0.64 to 1.31) 0.57
  IL-3 1.62 (1.14 to 1.62) 1.62 (1.1 to 1.62) 0.78
  IL-4 2.6 (1.72 to 5.24) 3.955 (2.18 to 5.24) 0.54
  IL-5 1.28 (0.84 to 1.72) 0.96 (0.84 to 1.72) 0.83
  IL-7 4.16 (2.99 to 5.59) 4.89 (3.52 to 7.94) 0.13
  IL-9 0.77 (0.77 to 1.94) 0.77 (0.77 to 1.94) 0.86
  IL-10 22.02 (16.77 to 40.28) 33.05 (12.91 to 44.83) 0.83
  IL-13 1.95 (1.67 to 2.8) 1.98 (1.66 to 2.8) 0.81
  IL-17a 1.23 (1.23 to 1.34) 1.23 (1.23 to 1.34) 0.78
  sCD40L 284.5 (207.5 to 466.5) 285 (204.75 to 483) 0.83
  TNFβ 1.04 (1.04 to 3.95) 1.04 (1.04 to 3.95) 0.97
Chemokines Eotaxin 37.95 (21.05 to 48.53) 31.46 (26.64 to 48.93) 0.92
  Fractalkine 37.96 (30.03 to 52.69) 39.61 (22.83 to 48.54) 0.62
  GRO 69.91 (47.16 to 252) 129 (78.92 to 246.25) 0.31
  IL-8 61.85 (28.05 to 234.75) 51.69 (37.24 to 80.03) 0.66
  MCP-1 762.5 (544 to 1,661.25) 792 (668.75 to 1,340.5) 0.92
  MCP-3 7.18 (5.7 to 9.81) 9.81 (7.5 to 10.66) 0.04
  MDC 1004.5 (715 to 1,126.75) 695 (554.5 to 867.25) 0.10
  MIP-1α 21.21 (3.51 to 47.18) 10.5 (3.51 to 16.46) 0.31
  MIP-1β 43.44 (8.13 to 111.17) 24.42 (12.89 to 45.65) 0.46
  RANTES 47.21 (19.68 to 178.01) 55.76 (33.4 to 101.35) 0.71
Growth factors EGF 2.72 (2.72 to 10.12) 2.72 (2.72 to 7.25) 0.58
  Flt-3 L 70.25 (4.16 to 82.49) 51.82 (23.89 to 77.59) 0.45
  GCSF 3.26 (3.24 to 16.04) 3.24 (3.23 to 12.33) 0.69
  GMCSF 2.79 (1.88 to 9.33) 2.22 (1.74 to 7.24) 0.63
  PDGF-AA 6.94 (5.87 to 7.78) 10.38 (7.4 to 17.71) 0.03
  PDFG-BB 1.79 (0.41 to 1.79) 1.79 (1.79 to 3.2) 0.23
  TGF-α 7.09 (6.64 to 8.21) 7.0 (5.62 to 9.1) 0.62
  FGF-2 13.4 (11.67 to 16.8) 16.92 (13.4 to 20.24) 0.09
  VEGF 11.3 (6.92 to 16.92) 11.67 (10.28 to 22.29) 0.47
  1. Data presented as median concentration (pg/ml) (25th to 75th percentile). Permutation analysis: significance analysis of microarrays for Excel, Wilcoxon rank-sum test. Significant results are in bold, taken as P <0.05. EGF, epidermal growth factor; FGF, fibroblast growth factor; Flt, FMS-like tyrosine kinase; GCSF, granulocyte colony-stimulating factor; GMCSF, granulocyte–macrophage colony-stimulating factor; GRO, growth regulated oncogene; IFN, interferon; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; IP-10, Interferon gamma induced protein 10; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; SSc, systemic sclerosis; TGF-α, transforming growth factor alpha; TNF-α, tumour necrosis factor alpha; VEGF, vascular endothelial cell growth factor.